FDA Grants Satraplatin Priority Review
This article was originally published in The Pink Sheet Daily
Executive Summary
GPC Biotech completed rolling NDA in February; action date on novel platinum-based oncologic is Aug. 15.
You may also be interested in...
GPC Satraplatin Data Show Reduction In Disease Progression In Prostate Cancer
Data presented at ASCO is part of a Phase III registrational trial for the platinum-based chemotherapy.
GPC Satraplatin Data Show Reduction In Disease Progression In Prostate Cancer
Data presented at ASCO is part of a Phase III registrational trial for the platinum-based chemotherapy.
Bristol-Myers Squibb Looks To Feed Oncology Pipeline With New Protein Class
Discovery and development deal could be worth up to $1.3 billion for Waltham, Mass.-based Adnexus.